Scientific exchange · Dr. Benedikt Dubois

24 Feb 2026 · In person · Dr. Benedikt Dubois, LMU Klinikum München · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0042MI request

Capture insight from this engagement

Location: LMU Klinikum München
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response
Chemotherapy-free first line
Comparator checkpoint monotherapy

Scientific content used

VTX core scientific deck v3.2
VOYAGE-1 pivotal data summary

Questions raised

No questions recorded.

Notes

Scientific exchange with thoracic medical oncologist at LMU Klinikum München. Discussed duration of response, chemotherapy-free first line, comparator checkpoint monotherapy.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 1
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0042

Audit history (0)

All create, update and approval events for this record

No audit events in sample data